(STOK) Stoke Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.887m USD | Total Return: 208.8% in 12m
Avg Turnover: 16.2M
Qual. Beats: 0
Rev. Trend: 80.3%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -53.4 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -13.96 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Confidence
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on treating severe genetic diseases through protein upregulation. The firm utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to develop antisense oligonucleotides (ASOs) designed to restore protein levels in patients with haploinsufficiency diseases.
The company’s lead candidate, Zorevunersen (STK-001), is currently in Phase 3 clinical trials for Dravet syndrome, a rare form of epilepsy. A second candidate, STK-002, is in Phase 1 trials for autosomal dominant optic atrophy. Stoke operates under a capital-intensive research and development model typical of the biotech sector, leveraging strategic partnerships with Biogen and Acadia Pharmaceuticals to share the costs and risks of commercialization.
ASO-based therapies represent a specialized segment of the precision medicine market, targeting the underlying genetic cause of a disease rather than managing symptoms. To gain a deeper perspective on the companys valuation and growth potential, investors may find it useful to consult ValueRay. Headquartered in Bedford, Massachusetts, the company continues to expand its pipeline toward various central nervous system and ocular targets.
- Zorevunersen Phase 3 trial milestones for Dravet syndrome dictate near-term valuation
- Biogen and Acadia partnership milestones provide essential non-dilutive capital funding
- TANGO platform validation hinges on STK-002 clinical efficacy in optic atrophy
- Regulatory approval pathways for antisense oligonucleotides impact long-term commercial viability
- R&D expenditure and cash runway sensitive to high clinical trial costs
| Net Income: -169.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA -50.33 > 1.0 |
| NWC/Revenue: 1.02k% < 20% (prev 173.4%; Δ 842.4% < -1%) |
| CFO/TA -0.33 > 3% & CFO -146.8m > Net Income -169.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.1m) vs 12m ago 6.17% < -2% |
| Gross Margin: 87.07% > 18% (prev 0.98%; Δ 8.61k% > 0.5%) |
| Asset Turnover: 7.55% > 50% (prev 46.92%; Δ -39.37% > 0%) |
| Interest Coverage Ratio: -53.37 > 6 (EBITDA TTM -178.2m / Interest Expense TTM 3.41m) |
| A: 0.74 (Total Current Assets 366.7m - Total Current Liabilities 40.8m) / Total Assets 443.3m |
| B: -1.24 (Retained Earnings -547.7m / Total Assets 443.3m) |
| C: -0.43 (EBIT TTM -181.8m / Avg Total Assets 425.1m) |
| D: -11.32 (Book Value of Equity -547.8m / Total Liabilities 48.4m) |
| Altman-Z'' = -13.96 = D |
| DSRI: 60.31 (Receivables 6.14m/606k, Revenue 32.1m/190.9m) |
| GMI: 1.12 (GM 87.07% / 97.69%) |
| AQI: 2.74 (AQ_t 0.16 / AQ_t-1 0.06) |
| SGI: 0.17 (Revenue 32.1m / 190.9m) |
| TATA: -0.05 (NI -169.8m - CFO -146.8m) / TA 443.3m) |
| Beneish M = 46.27 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 29.67 with a total of 397,403 shares traded.
Over the past week, the price has changed by -2.46%,
over one month by -18.27%,
over three months by -19.02% and
over the past year by +208.84%.
Stoke Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy STOK.
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45.1 | 52% |
P/S = 58.8162
P/B = 4.7759
Revenue TTM = 32.1m USD
EBIT TTM = -181.8m USD
EBITDA TTM = -178.2m USD
Long Term Debt = 990k USD (estimated: total debt 3.42m - short term 2.43m)
Short Term Debt = 2.43m USD (from shortTermDebt, last quarter)
Debt = 5.86m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.43m
Net Debt = -337.7m USD (calculated: Debt 5.86m - CCE 343.5m)
Enterprise Value = 1.55b USD (1.89b + Debt 5.86m - CCE 343.5m)
Interest Coverage Ratio = -53.37 (Ebit TTM -181.8m / Interest Expense TTM 3.41m)
EV/FCF = -10.49x (Enterprise Value 1.55b / FCF TTM -147.7m)
FCF Yield = -9.53% (FCF TTM -147.7m / Enterprise Value 1.55b)
FCF Margin = -460.4% (FCF TTM -147.7m / Revenue TTM 32.1m)
Net Margin = -529.2% (Net Income TTM -169.8m / Revenue TTM 32.1m)
Gross Margin = 87.07% ((Revenue TTM 32.1m - Cost of Revenue TTM 4.15m) / Revenue TTM)
Gross Margin QoQ = 83.19% (prev 24.75%)
Tobins Q-Ratio = 3.49 (Enterprise Value 1.55b / Total Assets 443.3m)
Interest Expense / Debt = 58.16% (Interest Expense 3.41m / Debt 5.86m)
Taxrate = 21.0% (US default 21%)
NOPAT = -143.6m (EBIT -181.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.99 (Total Current Assets 366.7m / Total Current Liabilities 40.8m)
Debt / Equity = 0.01 (Debt 5.86m / totalStockholderEquity, last quarter 394.9m)
Debt / EBITDA = 1.89 (negative EBITDA) (Net Debt -337.7m / EBITDA -178.2m)
Debt / FCF = 2.29 (negative FCF - burning cash) (Net Debt -337.7m / FCF TTM -147.7m)
Total Stockholder Equity = 347.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.94% (Net Income -169.8m / Total Assets 443.3m)
RoE = -18.96% (Net Income TTM -169.8m / Total Stockholder Equity 895.3m)
RoCE = -20.28% (EBIT -181.8m / Capital Employed (Equity 895.3m + L.T.Debt 990k))
RoIC = -40.68% (negative operating profit) (NOPAT -143.6m / Invested Capital 353.0m)
WACC = 9.70% (E(1.89b)/V(1.89b) * Re(9.73%) + (debt cost/tax rate unavailable))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 16.23%
[DCF] Fair Price = unknown (Cash Flow -147.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 80.32 | Revenue CAGR: 241.2% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.76 | Chg30d=+6.68% | Revisions=+33% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.81 | Chg30d=+6.56% | Revisions=+33% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.25 | Chg30d=+3.54% | Revisions=+20% | GrowthEPS=-2607.4% | GrowthRev=-85.8%
EPS next Year (2027-12-31): EPS=-3.10 | Chg30d=+2.28% | Revisions=+0% | GrowthEPS=+4.5% | GrowthRev=+76.2%
[Analyst] Revisions Ratio: +33%